Orchard in License Agreements for Stable Cell Line Technology from Glaxo
15 Luglio 2020 - 02:00PM
Dow Jones News
By Michael Dabaie
Orchard Therapeutics said it is in license agreements with
GlaxoSmithKline PLC.
The agreements are for use of Glaxo's lentiviral stable cell
line technology for Orchard's investigational hematopoietic stem
cell gene therapies for Wiskott Aldrich syndrome and
transfusion-dependent beta thalassemia.
Orchard said it plans to submit a biologics license application
and marketing authorization application for OTL-103 for the Wiskott
Aldrich syndrome in the U.S. and EU, respectively, in 2021.
Orchard said it doesn't expect the terms of the license to have
a material impact on Orchard's financial position or near-term cash
needs.
Orchard ADRs were up 8% to $5.54 premarket.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 15, 2020 07:45 ET (11:45 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2023 a Mar 2024